• 한국군사과학기술학회지
• /
• 제25권2호
• /
• pp.210-217
• /
• 2022

Chemical warfare agents(CWA) such as nerve agents and vesicating agents show lethality by skin contamination. Skin protection, therefore, is one of the top priorities to deal with the growing threat from CWA. In an attempt to develop the most effective topical skin protectant(TSP), candidate substances including PFPE(perfluorinated polyether), PTFE(polytetrafluoroethylene), glycerin, and polysaccharides were evaluated in forms of various formulations against nerve agent simulant DMMP(dimethylmethyl phosphonate) penetration. The protective efficacy of the formulation against DMMP penetration was estimated as the onset time of color change of the KM9 chemical agent detection paper. Based on this study, it was found that several PFPE- and glycerin-based formulations exhibit remarkably superior efficacy as a protective cream. This protective cream is expected to be used as TSP for military application after further research.

• 한국정보처리학회:학술대회논문집
• /
• 한국정보처리학회 2023년도 춘계학술발표대회
• /
• pp.647-649
• /
• 2023

Sentiment analysis as part of natural language processing (NLP) has received much attention following the demand to understand people's opinions. Aspect-based sentiment analysis (ABSA) is a fine-grained subtask from sentiment analysis that aims to classify sentiment at the aspect level. Throughout the years, researchers have formulated ABSA into various tasks for different scenarios. Unlike the early works, the current ABSA utilizes many elements to improve performance and provide more details to produce informative results. These ABSA formulations have provided greater challenges for researchers. However, it is difficult to explore ABSA's works due to the many different formulations, terms, and results. In this paper, we conduct a comparative analysis of recent studies on ABSA. We mention some key elements, problem formulations, and datasets currently utilized by most ABSA communities. Also, we conduct a short review of the latest papers to find the current state-of-the-art model. From our observations, we found that span-level representation is an important feature in solving the ABSA problem, while multi-task learning and generative approach look promising. Finally, we review some open challenges and further directions for ABSA research in the future.

• 한국미생물·생명공학회지
• /
• 제26권4호
• /
• pp.369-372
• /
• 1998

Microbial insecticide formulations were prepared by liquid and semi-solid fermentations using Bacillus thuringiensis subsp. kurstaki, HL-106 (BTK-HL106), B. thuringiensis subsp. israelensis HL-63 (BTI-HL63) and B. sphaericus 1593 (BS-1593) strains. The liquid fermentation medium contained molasses 2%, dextrose 1.5%, peptone 2%, D-xylose 0.025%, CaCl$_2$ 0.1%, K$_2$HPO$_4$ 0.1%, KH$_2$PO$_4$ 0.1%, MgSO$_4$$.$7H$_2$O 0.03%, FeSO$_4$$.$7H$_2$O 0.002%, ZnSO$_4$$.$7H$_2$O 0.02%. The composition of the semi-solid fermentation medium was rice bran 45.2%, zeolite 31%, yeast powder 0.02%, corn powder 5%, dextrose 3%, lime 0.3%, NaCl 0.06%, CaCl$_2$ 0.02%, and H$_2$O 15.42%. Insecticide formulations produced in the liquid fermentation named BTK-HL106, BTI-HL63 and BS-1593 pesticides and those in the semi-solid fermentation were designated as BTK-HL106-1, BTI-HL63-1 and BS-1593-1 pesticides, respectively. The number of spore (endotoxin crystals) was 2.65${\times}$10$\^$9/ spores per $m\ell$ in the BTK-HL106 and 3.5${\times}$10$\^$10/ in the BTK-HL106-1 3.8${\times}$10$\^$9/ spores in the BTI-HL63 and 7.0${\times}$10$\^$10/ in the BTI-HL63-1, and 7.5${\times}$10$\^$9/ in the BS-1593 and 1.4${\times}$10$\^$10/ in the BS-1593-1. The spores in the BS-1593 formulation was produced two times more than the other formulations. The spores in the BTI-HL63-1 were contained twice than those in the BTK-HL106-1, and five times than those in the BS-1593-1. The results indicated that spore (endotoxin crystals) productions in the semi-solid fermentation increased about ten times than those in the liquid fermentations. $LC_{50}$s of the BTI-HL63 and BS-1593 were 4.5 $\mu\textrm{g}$, and those of the BTI-HL63-1 and BS-1593-1 were 1.5 $\mu\textrm{g}$. $LC_{50}$ of the BTK-HL106 was 1.5 mg and that of the BTK-HL106-1 was 0.9 mg. The $LC_{50}$s of the formulations in the semi-solid fermentations showed about two to three times higher than those in the liquid fermentations.

• Journal of Pharmaceutical Investigation
• /
• 제28권3호
• /
• pp.185-191
• /
• 1998

A bioequivalence study of the Loxipen tablets (Dae Wha Pharmaceutical Co., Korea) to the Loxonin tablets (Dong Hwa Pharmaceutical Co., Korea), formulations of sodium loxoprofen anhydrous 60 mg, was conducted. Sixteen healthy Korean male subjects received each formulation at the dose of 60 mg as sodium loxoprofen anhydrous in a $2{\times}2$ crossover study. There was a 2-week washout period between the dose. Plasma concentrations of loxoprofen were monitored by an HPLC method for over a period of 6 h after each administration. AUC (area under the plasma concentration-time curve from time zero to infinity) was calculated by the linear trapezoidal and extrapolation method. $C_{max}$ (maximum plasma drug concentration) and $T_{max}$ $(time\;to\;reach\;C_{max})$ were compiled from the plasma drug concentration-time data. Analysis of variance (ANOVA) revealed that there are no differences in AUC, $C_{max}$ and $T_{max}$ between the formulations. The apparent differences between the formulations in these parameters were all far less than 20% (i.e., 5.88, 7.81 and 6.09% for AUC, $C_{max}$ and $T_{max}$, respectively). Minimum detectable differences (%) at ${\alpha}=0.1$ and $1-{\beta}=0.8$ were all less than 20% difference in these parameters between the formulations were all over 0.8 (i.e., 15.81, 13.13 and 19.85 for AUC, $C_{max}$ and $T_{max}$, respectively). The 90% confidence intervals for these parameters were also within ${\pm}20%$ (i.e., $-16.52{\sim}4.77$, $-16.65{\sim}1,02$ and $-19.45{\sim}7.28%$ for AUC, $C_{max}$ and $T_{max}$, respectively). These results satisfy the bioequivalence criteria of the Korea Food and Drug Administration (KFDA) guidelines (No. 98-51). Therefore, these results indicate that the 2 formulations of loxoprofen are bioequivalent and, thus, may be prescribed interchangeably.

• 농약과학회지
• /
• 제16권2호
• /
• pp.163-170
• /
• 2012

Buprofezin과 조합된 8종의 합제와 buprofezin을 포함하지 않은 11종의 단제 즉, 등록된 총 19종의 살충제를 대상으로 귤가루깍지벌레(Planococcus citri)의 약충과 성충에 분무처리하여 살충효과를 평가하였다. Buprofezin과 조합된 합제가운데 귤가루깍지벌레의 약충과 성충에 대해 93% 이상의 높은 살충활성을 나타내는 것은 5조합(buprofezin 15EC+acetamiprid 4EC, buprofezin 10SC+clothianidin 3SC, buprofezin 20WP+dinotefuran 15WP, buprofezin 20SC+thiacloprid 5SC, buprofezin 20SC+thiamethoxam 3.3SC) 이었다. 유기인계 약제 3종(EPN 45EC, fenitrothion 50EC 및 methidathion 40EC)은 약충에 대해서만 90~93%의 살충활성을 나타내었으며, 네오니코티노이드계 약제 4종(acetamiprid 8WP, clothianidin 8SC, dinotefuran 20WG 및 thiamethoxam 10WG)도 약충에 대해서만 90% 이상의 살충활성을 나타내었다. 그리하여 buprofezin과 조합된 8종의 합제가운데 93% 이상의 살충활성을 나타낸 5종 합제의 시설하우스 토마토와 장미에 대한 침투이행성과 잔효성 검정에서 모두 60% 이하의 낮은 살충활성을 나타내었다. 또한 시설하우스 장미에서 buprofezin과 조합된 5종 합제의 방제효과는 5일차까지 90% 이상, 10일차까지 80% 이상, 15일차까지 70% 이상으로 높게 나타났다.

• 한국수의병리학회:학술대회논문집
• /
• 한국수의병리학회 2002년도 추계학술대회초록집
• /
• pp.5-6
• /
• 2002

유럽에서 돼지 번식 효율 증진과 비육을 위한 적절한 활용방법과 몇 가지 잘 조제된 한약제가 규격화되어 나왔다. 이 자료에는 한약제의 효능의 기준을 비롯하여 위생에 대해서도 제시하고 있다. 대학 및 연구기관, 임상 수의사들과 사료업체들이 수행했던 지난 수년간의 실험과 연구 결과를 토대로 돼지 번식효율 증진을 위한 한약제를 사료첨가제로 활용하여 최적화시켰다. 유럽의 수의분야에서 사용되었던 4가지의 특정 한약제를 기본으로 하여 돼지 사양에 있어서 가장 중요한 문제들의 대부분이 성공적으로 해결되었다. 즉 수정률, 호흡기질병, 설사와 스트레스에 관한 문제들인데 면역이 억압되고 저질의 자돈이 생산됨에 따라 생산성 저하에 따른 엄청난 경제적인 손실을 대처할 수 있다. 또한 일반적인 임상증상을 치료하면서 동시에 가장 중요한 것 중의 하나는 자기방어체계를 증진시킨다는 것이다. 이로써 동물의 면역력과 활력을 증가시키고 건강을 유지시켜서 폐사율을 감소시킨다. 게다가 여기에서 제시된 자료들은 일상적으로 사용되었던 항생제나 호르몬제제들의 사용을 대체할 수 있는 한약제들인데 고효율임이 증명되었다. 이러한 한약제들은 백신 프로그램이나 성장을 촉진시키는 인자들과 상호보완 상승작용도 가져 온다.

• Journal of Pharmaceutical Investigation
• /
• 제28권4호
• /
• pp.283-288
• /
• 1998

Lovastatin, one of the potent cholesterol-lowering agents, is an inactive lactone prodrug which is metabolized to its active open acid, lovastatin acid (LVA). Bioequivalence study of two lovastatin preparations, the test drug ($Mevacor^{\circledR}$: Chungwae Pharmaceutical Co., Ltd.) and the reference drug ($Lovaload^{\circledR}$: Chong Kun Dang Pharmaceutical Co., Ltd.), was conducted according to the guidelines of Korea Food and Drug Administration (KFDA). Fourteen healthy male volunteers, $23.9{\pm}3.9$ years old and $67.6{\pm}8.0$ kg of body weight in average, were divided randomly into two groups and administered the drug orally at the dose of 160 mg as lovastatin in a $2{\times}2$ crossover study. Plasma concentrations of lovastatin acid were analysed by HPLC method for 12 hr after administration. The extent of bioavailability was obtained from the plasma concentration-time profiles of total lovastatin acid after alkaline hydrolysis of the plasma samples. By alkaline hydrolysis, trace amounts of unmetabolized lovastatin were converted to lovastatin acid. The $AUC_{0-12hr}$ was calculated by the linear trapezoidal rule method. The $C_{max}$ and $T_{max}$ were compiled directly from the plasma drug concentration-time data. Student's t-test indicated no significant differences between the formulations in these parameters. Analysis of variance (ANOVA) revealed that there were no differences in AUC, $C_{max}$, and $T_{max}$ between the formulations. The apparent differences between the formulations were far less than 20% (e.g., 7.07, 5.77 and 1.18% for AUC, $C_{max}$, and $T_{max}$, respectively). Minimum detectable differences(%) between the formulations at ${\alpha}=0.05$ and $1-{\beta}=0.8$ were less than 20% (e.g., 17.2, 15.1, and 15.9% for AUC, Cmax, and Tmax, respectively). The 90% confidence intervals for these parameters were also within ${\pm}20%$ (e.g.. $-5.20{\sim}19.3$, $-5.00{\sim}16.5$, and $-10.2{\sim}12.5%$ for AUC, $C_{max}$, and $T_{max}$, respectively). These results satisfied the bioequivalence criteria of KFDA guidelines, indicating that the two formulations of lovastatin were bioequivalent.

• 농약과학회지
• /
• 제9권1호
• /
• pp.81-87
• /
• 2005

Ethaboxam[(RS)-N-(a-cyano-2-thenyl)-4-ethyl-2-(ethylamino)-1,3-thiazole-5-carboximide]은 난균강 미생물에 대하여 우수한 살균활성을 보이는 신규 살균제이다. Ethaboxam 원제와 몇 가지 ethaboxam 제형의 배추 뿌리혹병에 대한 방제효과를 조사하였다. Ethaboxam을 관주처리 하였을 때, 토양 1 L 당 8.33 mg 농도 처리구는 배추 뿌리의 혹 형성이 완전히 억제되었으며, $EC_{50}$ 값은 2.65 mg/L 토양이었다. Ethaboxam 5개 제형(10% 액상수화제, 15% 액상수화제, 2% 입제, 5% 입제, 25% 수화제) 그리고 ethaboxam과 metalaxyl 합제 제형(3%+1% 입제)의 배추 뿌리혹병 방제효과는 우수하였다. 이들 중 토양 관주처리 한 ethaboxam의 10% 및 15% 액상수화제, 토양 혼화처리 한 ethaboxam 2% 입제 제형은 다른 제형보다 배추 뿌리혹병에 대하여 더 우수한 방제효과를 보였다. 이들의 배추 뿌리혹병에 대한 $EC_{50}$ 값은 원제기준으로 토양 L 당 각각 3.72 mg(10% 액상수화제), 1.10 mg (15% 액상수화제), 4.95 mg (2% 입제) 이었다. 그러므로 실험한 ethaboxam 6개 제형 중에 15% 액상수화제가 배추 뿌리혹병에 대하여 가장 우수한 방제효과를 나타냄을 알 수 있었다. 이들 결과로부터 ethaboxam은 포장에서도 배추 뿌리혹병을 효과적으로 방제할 수 있으리라 생각되었다.

• Journal of the Korean Academy of Child and Adolescent Psychiatry
• /
• 제14권1호
• /
• pp.3-11
• /
• 2003

주의력결핍/과잉행동장애는 소아 청소년기의 가장 흔한 정신 장애이다. 이 장애의 기본 증상 및 이차 증상으로 인하여 본 장애를 가진 아동들은 학교 생활의 어려움, 학업성취도의 저하, 가족이나 친구관계 등 대인관계의 문제를 보이며, 장애가 적절하게 치료되지 않으면, 우울증과 같은 이차적인 정신장애로 발전하기도 하며, 물질남용, 행동장애, 반사회적 인격장애 등과 같은 장애와도 연관되어 있다. 현재까지 주의력결핍/과잉행동장애 치료로 가장 선호되는 것은 메칠페니데이트나 암페타민 등의 중추신경자 극제이다. 이들 약제의 작용기전은 여전히 불분명한 부분도 있으나, 대체적으로 뇌에서 도파민 등의 카테콜아민 농도를 증가시켜서 시냅스 효율을 높히는 것으로 알려져 있다. 효과 측면에서도 정신약물학 분야에서 본 중추신경자극제에 의한 주의력결핍/과잉행동장애의 치료는 정신질환의 어떤 치료법보다도 효과적이다. 지금까지 중추신경자극제의 최대 단점은 짧은 작용시간으로 인하여 하루에도 여러 차례 복용을 해야 한다는 것이다. 이로 인하여 본 약제를 복용하는 아동들은 동료로 부터 문제아로 낙인이 찍힐 가능성이 높으며, 낮은 약물 순응도, 사회적 편견 등에 노출될 가능성이 높았다. 이로 인하여 중추신경자극제의 장기 제형 개발은 꾸준히 시도되었고, 최근에는 본 장애의 병태생리에 대한 새로운 연구결과를 반영한 보다 진보된 형태의 장기 작용형 중추신경자극제가 등장하였다. 본 고찰에서는 이들 제형들의 특징을 소개하였다. 이들 새로운 제형의 중추신경자극제들은 주의력결핍/과잉행동장애를 가진 아동 뿐만 아니라 장애아의 부모나 학교 교사에도 큰 도움을 줄 것으로 기대한다.

• Journal of Pharmaceutical Investigation
• /
• 제29권3호
• /
• pp.241-245
• /
• 1999

Bioequivalence study of two cefpodoxime preparations, the test drug ($Banan^{\circledR}$: Hanil Pharmaceutical Co., Ltd.) and the reference drug ($Podox^{\circledR}$: Chong Kun Dang Pharmaceutical Co., Ltd.), was conducted according to the guidelines of Korea Food and Drug Administration (KFDA). Sixteen healthy male volunteers, $23.8{\pm}2.13$ years old and $63.34{\pm}4.84kg$ of body weight in average, were divided randomly into two groups and administered the drug orally at the dose of 200 mg as cefpodoxime proxetil in a $2{\times}2$ crossover study. Plasma concentrations of cefpodoxime were analysed by HPLC method for 12 hr after administration. The $AUC_{0-12hr}$ was calculated by the linear trapezoidal rule method. The $C_{max}$, and $T_{max}$ were compiled directly from the plasma drug concentration-time data. Student's t-test indicated no significant differences between the formulations in these parameters. Analysis of variance (ANOVA) revealed that there were no differences in AUC, $C_{max}$, and $T_{max}$ between the formulations. The apparent differences between the formulations were far less than 20% (e.g., 4.31, 1.99 and 4.30% for AUC, $C_{max}$, and $T_{max}$, respectively). Minimum detectable differences (%) between the formulations at ${\alpha}=\;0.05$ and $1-{\beta}=\;0.8$ were less than 20% (e.g., 13.89, 13.88, and 16.97% for AUC, $C_{max}$, and $T_{max}$, respectively). The 90% confidence intervals for these parameters were also within ${\times}20%$ (e.g., $-5,58{\sim}14.20$, $-7.89{\sim}11.88$, and $-7.78{\sim}16.38%$ for AUC, $C_{max}$, and $T_{max}$, respectively). These results satisfied the bioequivalence criteria of KFDA guidelines, indicating that the two formulations of cefpodoxime were bioequivalent.